(Reuters) – A U.S. Centers for Disease Control and Prevention advisory panel is set to meet on Wednesday to discuss the use of a booster dose of Pfizer and BioNTech’s COVID-19 vaccine for children aged 12 to 15 years, according to the agency’s website https://www.cdc.gov/vaccines/acip/index.html.
The Food and Drug Administration gave emergency use authorization to Pfizer’s booster for youth as young as 12 years old on Monday as coronavirus cases continued to surge due in large part to the spread of the Omicron variant.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Ramakrishnan M.)
Comments